MGD024
Near Add Your Location
Accepting patients
MGD024
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
- Bispecific Antibody
- Phase 1
Showing 1-1 of 1